Upcoming Financial Results Announcement by Beyond Air
Beyond Air, Inc. (NASDAQ: XAIR), a pioneering company in the medical device and biopharmaceutical sectors, has announced an important upcoming event. The company is scheduled to report its financial results for the second fiscal quarter ended September 30, 2025. The announcement will take place on Monday, November 10, 2025, followed by a conference call and webcast at 4:30 PM Eastern Time.
Join the Conference Call and Webcast
Interested stakeholders can participate in this conference call by dialing the numbers provided. For domestic callers, the number is 1-877-407-0784, while international participants can reach out at 1-201-689-8560. The company’s conference ID is 13756730. This is a valuable opportunity for investors and interested parties to gain insights directly from the management team.
Webcast Access
A webcast of the conference call will be available on the company’s website, specifically in the Events section, and a replay will be accessible shortly after the live call concludes. This ensures that stakeholders unable to attend can still stay informed about the company's performance and future outlook.
About Beyond Air, Inc.
Beyond Air, Inc. is dedicated to improving the health of patients dealing with respiratory challenges and neurological disorders through its innovative technologies. The company specializes in harnessing both endogenous and exogenous nitric oxide (NO) to treat life-threatening conditions. One key development is the approval of its LungFit™ PH system, which is designed to help term and near-term neonates suffering from hypoxic respiratory failure.
Current Clinical Advancements
In addition to its approved system, Beyond Air is actively engaging in clinical trials aimed at addressing severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria (NTM). The company also collaborates with The Hebrew University of Jerusalem to enhance research on autism spectrum disorders and other neurological issues, reflecting its commitment to addressing significant unmet medical needs.
Future Directions and Innovations
With an affiliate, Beyond Cancer, the exploration of ultra-high concentrations of nitric oxide using proprietary delivery systems may soon revolutionize the treatment landscape for certain solid tumors. This innovative approach underscores the company's broader goals of ensuring effective therapies for various health conditions.
Continued Commitment to Patients
Beyond Air’s dedication to patient health remains at the forefront as it develops technologies designed to make a meaningful impact on health outcomes. The combination of cutting-edge research and clinical expertise helps the company navigate the complexities of the biopharmaceutical sector while staying true to its mission.
Contact Information
For further inquiries, individuals may reach out to Corey Davis, Ph.D. at LifeSci Advisors, LLC. He can be contacted via email at Cdavis@lifesciadvisors.com or by phone at (212) 915-2577.
Frequently Asked Questions
What is the date of the financial results announcement?
The financial results for Q2 2026 are set to be announced on November 10, 2025.
How can I listen to the conference call?
You can listen to the conference call by calling the domestic number 1-877-407-0784 or the international number 1-201-689-8560.
What are the recent advancements by Beyond Air?
Beyond Air has received FDA approval for its LungFit™ PH system and is currently involved in clinical trials for treating severe lung infections.
Who can I contact for more information?
For further information, contact Corey Davis, Ph.D. at LifeSci Advisors, LLC via email or phone.
What is the role of nitric oxide in these treatments?
Nitric oxide is used in Beyond Air's therapies to enhance respiratory function and address neurological conditions, showcasing significant therapeutic potential.
